Evenity (Romosozumab) Hair and Skin Changes

What Hair and Skin Changes Does Romosozumab Actually Cause?

Romosozumab's prescribing information lists injection-site reactions as the most consistently reported dermatologic adverse event, occurring in approximately 5% of participants across the key FRAME and ARCH trials. Systemic skin reactions including hypersensitivity and rash occur at lower frequencies. Hair loss (alopecia) does not appear as a labeled adverse event in the current FDA package insert but has surfaced in post-marketing surveillance reports.

The distinction between labeled and post-marketing findings matters clinically. Labeled events carry frequency data from controlled trials. Post-marketing reports reflect spontaneous case submissions, making frequency estimates unreliable. For romosozumab, the short 12-month course reduces cumulative exposure compared to drugs taken indefinitely, which may explain why high-frequency hair or skin toxicity did not emerge in trials averaging roughly 5,000 participants per arm.

Injection-Site Reactions

Injection-site reactions (ISRs) are the most reproducible skin finding with romosozumab. In the FRAME trial (N=7,180), ISRs were reported by 5.1% of romosozumab-treated women versus 2.9% of placebo recipients [1]. The reactions are typically mild: erythema, pain, bruising, or localized edema appearing within hours of the 210 mg subcutaneous dose.

Clinically, ISRs rarely require discontinuation. Rotating injection sites between the abdomen, upper arm, and thigh, allowing the drug to reach room temperature before injection, and applying a cool compress after administration reduce incidence. Persistent or expanding erythema beyond 48 hours warrants assessment to distinguish ISR from cellulitis, though true cellulitis at romosozumab injection sites is exceedingly rare.

Systemic Hypersensitivity and Rash

Hypersensitivity reactions including urticaria and angioedema appear in the FDA labeling for romosozumab at a frequency characterized as uncommon [2]. Diffuse maculopapular rash, while not prominently featured in trial publications, has been described in pharmacovigilance databases. The mechanism likely involves immune recognition of the monoclonal antibody backbone rather than the sclerostin-binding domain specifically.

A patient reporting generalized urticaria or facial swelling within hours of an injection should be evaluated for anaphylaxis. Romosozumab should be permanently discontinued if a serious hypersensitivity reaction is confirmed.

The Biology Behind Hair and Skin Effects: Sclerostin and Wnt Signaling

Romosozumab inhibits sclerostin, a glycoprotein encoded by the SOST gene that normally suppresses Wnt/beta-catenin signaling in osteocytes [3]. Bone mineral density rises because osteoblast activity increases when sclerostin is blocked. The relevance to hair and skin is that Wnt/beta-catenin signaling is not exclusive to bone.

Wnt Signaling in Hair Follicle Cycling

Hair follicle cycling depends on tightly regulated Wnt/beta-catenin activity. Anagen (active growth) initiation requires Wnt pathway activation in dermal papilla cells, while premature Wnt suppression can shift follicles toward catagen (regression) [4]. Sclerostin is expressed in hair follicle outer root sheath cells, suggesting that blocking sclerostin could theoretically alter follicle behavior.

Whether systemic sclerostin inhibition at the doses used in romosozumab therapy produces follicle-level Wnt changes significant enough to cause observable alopecia in humans is unresolved. Animal studies using global SOST knockout models show altered skin phenotypes, but these represent lifelong complete sclerostin absence, a very different exposure profile than 12 monthly injections in a postmenopausal adult.

Wnt Signaling in Skin Homeostasis

Keratinocyte proliferation, epidermal barrier integrity, and wound healing all involve Wnt pathway crosstalk [5]. Sclerostin expression in the dermis has been confirmed in human tissue studies, but its functional role in mature skin remains an active area of basic science rather than established pharmacology. Clinicians should regard the Wnt-skin connection as a biologically plausible explanatory framework, not a confirmed mechanism for romosozumab skin toxicity.

The practical implication: if a patient on romosozumab reports diffuse hair thinning, a sclerostin-Wnt mechanism is scientifically plausible but cannot be attributed with certainty. Standard alopecia workup including thyroid function, ferritin, zinc, and hormonal panel should proceed in parallel because postmenopausal women starting romosozumab for severe osteoporosis overlap heavily with the population at risk for androgenetic and telogen effluvium hair loss regardless of drug exposure.

ARCH and FRAME Trial Data: What the Phase 3 Evidence Shows

ARCH Trial (NEJM 2017)

The ARCH trial enrolled 4,093 postmenopausal women with osteoporosis and assigned them to romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for 24 months [6]. The primary finding was a 48% reduction in new vertebral fractures in the romosozumab-to-alendronate group versus alendronate alone at 24 months (P<0.001). Hip fracture risk fell by 27% (P=0.002).

Dermatologic adverse events were not a primary or secondary endpoint in ARCH. Injection-site reactions in ARCH occurred in 4.2% of romosozumab participants. Skin-related serious adverse events were not reported at a frequency exceeding placebo in the published data, and no cluster of alopecia cases was described in the safety tables [6].

FRAME Trial (NEJM 2016)

FRAME randomized 7,180 postmenopausal women to romosozumab 210 mg monthly or placebo for 12 months [1]. New vertebral fractures occurred in 0.5% of romosozumab recipients versus 1.8% of placebo recipients at 12 months, a 73% relative risk reduction (P<0.001). The FRAME safety data table lists ISRs at 5.1% versus 2.9% and hypersensitivity at rates below 1% in both arms.

A key point for dermatologic counseling: neither FRAME nor ARCH was powered or designed to detect low-frequency adverse events. An event occurring in 0.3% of patients would require approximately 10,000 participants per arm to detect with 80% power, and neither trial reached that threshold for a single arm.

What Post-Marketing Data Add

The FDA Adverse Event Reporting System (FAERS) contains case reports linking romosozumab to alopecia, but FAERS data are hypothesis-generating only. Causality cannot be established from spontaneous reports because the denominator (total patients exposed) is imprecise, and confounders including concurrent medications and underlying conditions are incompletely captured [2].

The European Medicines Agency product information for Evenity notes hypersensitivity reactions and injection-site reactions as adverse drug reactions with defined frequency categories, but similarly does not list alopecia as a recognized adverse event with quantified incidence.

Comparing Romosozumab to Other Osteoporosis Agents on Skin Outcomes

Denosumab

Denosumab (Prolia, 60 mg SC every 6 months) carries a labeled risk of dermatitis, eczema, and rash, appearing in 4.3% of treated patients versus 3.5% of controls in key trials [7]. Serious skin infections including erythema, cellulitis, and leading to hospitalization are a boxed warning consideration for denosumab. Romosozumab does not carry a comparable serious skin infection warning.

Teriparatide and Abaloparatide

Teriparatide (Forteo, 20 mcg daily SC) and abaloparatide (Tymlos, 80 mcg daily SC) are both associated with injection-site reactions but not with systemic hair or skin changes in labeled adverse events [8]. Because these agents are injected daily rather than monthly, cumulative ISR frequency is higher in practice even if per-injection reaction rates are similar.

Bisphosphonates

Oral bisphosphonates such as alendronate and risedronate carry no meaningful dermatologic adverse event profile. Intravenous zoledronic acid (Reclast) is occasionally associated with a transient influenza-like reaction after first infusion that may include flushing, but sustained skin toxicity is not characteristic [9].

The practical takeaway for a patient who has experienced skin reactions on denosumab: romosozumab does not carry the same serious skin infection signal and may be a viable alternative, though the clinical indication (anabolic first versus antiresorptive first) and the cardiovascular boxed warning on romosozumab must also be weighed.

Clinical Management of Skin and Hair Complaints During Romosozumab Therapy

Grading and Initial Response

A clinician encountering a skin complaint during romosozumab therapy should grade severity using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [10]. Grade 1 (localized ISR, no systemic involvement) warrants observation and injection-technique review. Grade 2 (moderate local reaction, or mild systemic rash covering <30% body surface area) warrants antihistamine trial and closer follow-up. Grade 3 or higher (severe, generalized, or associated with systemic symptoms) warrants drug hold and specialist referral.

Managing Alopecia Reports

When a patient reports hair thinning during or after romosozumab, the differential is broad. Telogen effluvium following physiologic stress, iron deficiency, thyroid dysfunction, and androgenetic alopecia are all prevalent in the postmenopausal demographic and should be excluded before attributing hair loss to romosozumab.

Practical steps:

• Check TSH, free T4, ferritin, serum iron, TIBC, zinc, and a complete metabolic panel.
• Review the complete medication list for other alopecia-associated drugs (statins, beta-blockers, anticoagulants).
• Document timeline: did thinning begin within 2 to 4 months of starting romosozumab, or is it longer-standing?
• If no metabolic cause is found and temporal correlation is strong, dermatology referral for trichoscopy is appropriate.

Romosozumab's 12-month maximum course means that if hair loss is drug-related, spontaneous recovery after completing therapy is plausible, though no controlled data confirm a recovery timeline.

Injection-Site Reaction Prevention Protocol

The following technique modifications reduce ISR frequency based on general monoclonal antibody administration principles and the prescribing information recommendations [2]:

• Allow the pre-filled syringe to sit at room temperature for at least 30 minutes before injection.
• Clean the site with an alcohol swab and allow it to dry fully before injecting.
• Rotate injection sites systematically, keeping a log of prior sites.
• Apply a cool compress to the site for 10 minutes after injection.
• Avoid injecting into areas with active skin disease, bruising, or scarring.

Special Populations and Dermatologic Considerations

Patients with Pre-Existing Dermatologic Conditions

Patients with psoriasis, atopic dermatitis, or other inflammatory skin conditions were not studied as a subgroup in FRAME or ARCH. Wnt pathway involvement in both psoriasis pathogenesis and romosozumab's mechanism of action raises a theoretical question about whether sclerostin inhibition could modulate psoriasis activity, but no clinical data answer this question [5]. Dermatology co-management is advisable in patients with active moderate-to-severe skin disease starting romosozumab.

Postmenopausal Skin Physiology

Postmenopausal estrogen decline reduces skin collagen content by approximately 30% in the first 5 years after menopause and impairs wound healing [11]. This baseline skin vulnerability means that any drug-related skin insult in this population may be more apparent or take longer to resolve. Clinicians should document baseline skin status before starting romosozumab to distinguish pre-existing from drug-emergent changes.

Patients on Concurrent Hormone Therapy

Women on systemic estrogen-based hormone therapy (HRT) alongside romosozumab represent a clinically relevant overlap group because HRT partially restores skin collagen and may modify the dermatologic profile of any added therapy. No drug-drug interactions between romosozumab and estrogen preparations have been identified, but this combination has not been studied in a dedicated trial [2].

FDA Labeling Summary for Dermatologic Adverse Events

The current FDA-approved prescribing information for Evenity (romosozumab-aqqg) lists the following dermatology-relevant adverse events by frequency category [2]:

• Injection-site reactions: common (1 to 10%)
• Hypersensitivity reactions including urticaria and angioedema: uncommon (<1%)
• Dermatitis, rash, eczema: uncommon (<1%)
• Alopecia: not listed as a recognized adverse event

The cardiovascular boxed warning (increased risk of myocardial infarction and stroke) is the primary safety concern in the label and substantially outweighs skin events in clinical risk-benefit assessment. A patient who has had a myocardial infarction or stroke within the preceding 12 months should not receive romosozumab regardless of skin tolerability [2].

The Endocrine Society Clinical Practice Guideline on pharmacological management of osteoporosis, published in the Journal of Clinical Endocrinology and Metabolism, designates romosozumab as an appropriate first-line anabolic agent for very high fracture risk patients after cardiovascular risk screening, stating: "Romosozumab is recommended for patients at very high risk for fracture who do not have a recent history of myocardial infarction or stroke" [12].

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines similarly position romosozumab as a first-line anabolic option for severe osteoporosis, with a recommendation to assess and document cardiovascular risk before prescribing [13].